CD81

Across TCGA pan-cancer cohorts, CD81 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CD81 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CD81 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD81 expression acts as an unfavorable survival marker.

STAD are the cancer types where CD81 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

CD81–STAD (OS)

Open the STAD breakdown →